Gene Drive: Disease Control and Biosafety Duties

Science and Technology and Biosafety (Mains: General Studies-III) | News reference: 14 July 2026 (The Hindu analysis; updated 19 July) | Published: 23 October 2026

Scientists are exploring several ways to stop mosquito-borne diseases. One idea is to spread a genetic change that can affect the mosquito population or its ability to transmit disease. This is understood through the discussion of engineered gene drives. An analysis published on this subject in July 2026 raised questions of biosafety and public decision-making alongside the potential benefits. The main question is not only whether the technology can work in a laboratory; it is also how its impact will be assessed and what the role of affected people will be.

Why the July Discussion Matters

A scientific analysis published on 14 July 2026 and updated on 19 July discussed the development of gene drives and their risks. It drew attention to potential disease control, resistance and ecological effects. It was not a universal authorisation of any new product, nor a government announcement of open-environment use in India. Such a discussion should be taken as an understanding of the technology's concept and of preparedness for decision-making, not as a readily available public-health measure.

The World Health Organization issued guidance in 2021 for testing genetically modified mosquitoes. It places gene-drive technologies within the scope of evaluation. The 2018 decision of the Convention on Biological Diversity emphasised case-by-case risk assessment, risk management and, where appropriate, the participation and consent of affected local communities. The existence of these documents shows that scientific capability and social responsibility must advance together.

The Basic Meaning of Gene Drive

In a gene drive, the passage of a heritable element into the next generations is biased in its favour. In the usual Mendelian example, where a mother or father carries two different forms of a gene, the probability of one form reaching the offspring is generally understood to be half. Some gene-drive systems can spread at more than this normal probability. But not every gene, every organism and every situation can be understood from this single simple example.

The term gene drive is also used for natural biological processes. In modern biotechnology, the focus of discussion is often on human-made engineered or synthetic gene drives. Not all gene drives are built only with CRISPR. Similarly, the rise of a trait in a population is not by itself proof of a gene drive; other processes such as natural selection can also change the frequency of traits. Gene editing and gene drive should therefore not be treated as synonyms.

The Difference from Gene Editing

In gene editing, a targeted change can be made in an organism's genetic material. The special concern of a gene drive is linked to the biased spread of that change, or of a related heritable element, in a population. Not every modified organism carries a gene drive, and not every modification spreads rapidly into future generations. To understand a technology, one has to see what its goal is, how many generations it can persist for and in which conditions it can spread.

Some research approaches focus on reducing the population. Others aim to alter the capacity to transmit a pathogen rather than eliminate mosquitoes altogether. The benefits, risks and standards of success of the two will differ. A fall in mosquito numbers and a fall in human disease are not the same measure. Public-health benefit also requires suitable evidence of impact on disease; merely demonstrating the spread of a genetic element is not enough.

Potential Uses and Their Conditions

One reason for interest in gene drives is the control of diseases such as malaria. If a safe, effective and acceptable method were developed, it could complement existing measures. But a distinction must be kept between possibility and proven benefit. The limited conditions of a laboratory do not fully represent the diversity of the open environment. The genetic diversity of a natural population, the climate and local ecology can change the outcome.

The WHO's guidance emphasises the quality, safety, ethics and effectiveness of testing. This does not mean approving all modified mosquitoes or all gene drives for use. Permission for any particular product will depend on the relevant regulatory process and the evidence for that product. Reading promising results in the news and abandoning current measures such as bed nets, stopping water stagnation, disease surveillance and timely treatment would not be right.

Why There Should Be No Confusion with Wolbachia

Not all new mosquito-control technologies are engineered gene drives. The World Mosquito Program's Wolbachia method uses a naturally occurring bacterium. According to the programme's description, its method does not involve genetic modification of the mosquito or the bacterium. Describing this particular method as the same as a CRISPR-based gene-drive technique built by altering genetic material would be wrong.

At the same time, the scientific literature contains broad definitions of gene drive for natural hereditary bias. So rather than imposing a blanket prohibition on every biological use of the term, the process of the relevant method should be stated clearly. The useful distinction for the reader is whether a programme is based on introducing a bacterium or on an engineered genetic element. The evidence or approval of one technology cannot automatically be applied in favour of another.

At What Levels Are the Risks?

The first risk is the development of resistance. Changes or selection in a natural population can produce a response that weakens the expected effect. The second risk is spread beyond the intended area, where the movement and breeding of the relevant organisms will matter. The existence of an administrative boundary does not by itself create a biological boundary. The third risk is change in ecological relationships. Its assessment will have to be made according to the target organism and the local environment.

These risks do not mean that every gene drive will necessarily spread across the whole world. Scientific literature reports different capacities for spread and persistence in different systems. Some proposals are developed with the aim of remaining limited. Still, the intention of control and its actual evidence are different. An early risk cannot be discounted by treating any proposal for recall or correction as a certain solution. Reversing an effect in the open environment can be difficult.

The Meaning of Phased Testing

In phased testing, evidence on set criteria is examined before moving from one stage to the next. Biosafety, effectiveness, environmental impact and community-related questions are part of it. Good performance in a laboratory is not automatic permission for the next stage. Similarly, the result of one limited location will not be a sufficient basis for large-scale use in every area. Clear decision criteria are useful for researchers, regulators and the public alike.

There is a difference between risk assessment and risk management. In the first, the possible harm, its likelihood and the uncertainty are understood. In the second, arrangements are made to prevent or reduce the harm. Independent review, monitoring and arrangements for sharing results may be necessary. This article introduces these principles; it does not describe the process of creating any organism or releasing it into the open environment.

Consent and Public Decision-Making

The 2018 decision of the Convention on Biological Diversity calls for a cautious approach. It discusses scientifically sound, case-by-case risk assessment and risk management. Provisions relating to the free, prior informed consent or the participation of affected indigenous peoples and local communities are placed in the context of appropriateness, national circumstances and law. It would not be correct to declare this an identical new domestic legal process in every country.

Good communication is not merely telling people the benefits of a technology. It should also explain the uncertainty, the alternatives and the possible harms. People should be able to ask questions, and their concerns should enter the decision. Communities bearing the burden of disease should not be treated merely as testing grounds. Their role in the direction of research, monitoring and the distribution of benefits needs consideration. If cross-border effects are possible, the interests of neighbouring regions also matter.

The Direction of Policy for India

In India, the discussion can be used to strengthen the arrangements for scientific capacity, biosafety and disease control. This suggestion is not a claim about any current Indian product approval. Public institutions should explain the different levels of evidence in simple language: laboratory results, environmental assessment and impact on disease. Declaring a technology ready by combining these levels would weaken trust.

Dialogue among local scientists, public-health experts, environment experts and communities is essential. Monitoring capacity and the resources to carry responsibility over a long period are also important. Research on new technology and current disease control should not be rivals of each other. Taking the possibility of benefit seriously and examining the risks are both parts of responsible policy.

Practice for the Exam

Mains: "The public-health potential of gene drives cannot be assessed separately from biosafety and community participation." Discuss. (250 words, 15 marks)

Conclusion

A gene drive is a scientific possibility, not a ready-made solution for every disease. Its responsible understanding brings together the correct definition, suitable evidence, caution and public participation. Trust in a technology will be built not by exaggerating its benefits, but by honestly acknowledging uncertainty and by accountable decision-making.

Gene Drive: The Possibility of Disease Control and the Responsibility of Biosafety